Intellia Therapeutics Inc (NASDAQ:NTLA) CEO Nessan Bermingham sold 336,783 shares of the company’s stock in a transaction on Friday, December 8th. The stock was sold at an average price of $20.78, for a total transaction of $6,998,350.74. Following the completion of the transaction, the chief executive officer now directly owns 696,000 shares in the company, valued at approximately $14,462,880. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Nessan Bermingham also recently made the following trade(s):

  • On Wednesday, December 6th, Nessan Bermingham sold 111,500 shares of Intellia Therapeutics stock. The stock was sold at an average price of $20.34, for a total transaction of $2,267,910.00.

Intellia Therapeutics Inc (NASDAQ:NTLA) opened at $21.22 on Monday. Intellia Therapeutics Inc has a 12 month low of $10.83 and a 12 month high of $33.34.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The business had revenue of $7.30 million during the quarter, compared to analyst estimates of $5.83 million. During the same period in the prior year, the business posted ($0.22) earnings per share. The company’s revenue was up 49.0% on a year-over-year basis. research analysts expect that Intellia Therapeutics Inc will post -1.68 EPS for the current fiscal year.

NTLA has been the topic of several research analyst reports. Jefferies Group set a $42.00 price target on shares of Intellia Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 31st. Leerink Swann upped their price target on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, October 31st. They noted that the move was a valuation call. Barclays reaffirmed a “buy” rating on shares of Intellia Therapeutics in a report on Sunday, November 5th. ValuEngine cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Finally, Chardan Capital cut Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 target price on the stock. in a research note on Tuesday, August 29th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $30.17.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new stake in shares of Intellia Therapeutics during the second quarter worth about $101,000. Bank of Montreal Can boosted its holdings in shares of Intellia Therapeutics by 1,031.7% during the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after purchasing an additional 7,222 shares during the period. Nationwide Fund Advisors boosted its holdings in shares of Intellia Therapeutics by 117.7% during the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock worth $129,000 after purchasing an additional 4,351 shares during the period. Nisa Investment Advisors LLC purchased a new stake in shares of Intellia Therapeutics during the second quarter worth about $134,000. Finally, State of Wisconsin Investment Board purchased a new stake in shares of Intellia Therapeutics during the second quarter worth about $160,000. Institutional investors and hedge funds own 49.53% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Intellia Therapeutics Inc (NTLA) CEO Sells $6,998,350.74 in Stock” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/11/intellia-therapeutics-inc-ntla-ceo-sells-6998350-74-in-stock.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Receive News & Stock Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related stocks with our FREE daily email newsletter.